Stay updated with the latest panacea-biotec news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on panacea-biotec topics.
New Delhi: Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar, among others, have received either the vaccine or a placebo as part of the trial sponsored by the Indian Council of Medical Research (ICMR) and Pana ...Read More >
Representative Image: Currently, there is no antiviral treatment or licensed vaccine against dengue in India | Image: Bloomberg Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar among others have received eith ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.